- Home
- ENLT vs KYMR Comparison
ENLT vs KYMR Comparison
Compare ENLT & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- KYMR
- Stock Information
- Founded
- ENLT 2008
- KYMR 2015
- Country
- ENLT Israel
- KYMR United States
- Employees
- ENLT N/A
- KYMR N/A
- Industry
- ENLT
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- ENLT
- KYMR Health Care
- Exchange
- ENLT Nasdaq
- KYMR Nasdaq
- Market Cap
- ENLT 2.0B
- KYMR 1.8B
- IPO Year
- ENLT 2023
- KYMR 2020
- Fundamental
- Price
- ENLT $19.50
- KYMR $29.64
- Analyst Decision
- ENLT Buy
- KYMR Buy
- Analyst Count
- ENLT 3
- KYMR 15
- Target Price
- ENLT $19.67
- KYMR $55.47
- AVG Volume (30 Days)
- ENLT 28.0K
- KYMR 650.3K
- Earning Date
- ENLT 05-06-2025
- KYMR 05-09-2025
- Dividend Yield
- ENLT N/A
- KYMR N/A
- EPS Growth
- ENLT 90.47
- KYMR N/A
- EPS
- ENLT 0.98
- KYMR N/A
- Revenue
- ENLT $397,296,000.00
- KYMR $58,885,000.00
- Revenue This Year
- ENLT $355.90
- KYMR $32.80
- Revenue Next Year
- ENLT $42.83
- KYMR $8.88
- P/E Ratio
- ENLT $19.18
- KYMR N/A
- Revenue Growth
- ENLT 44.42
- KYMR N/A
- 52 Week Low
- ENLT $14.01
- KYMR $19.45
- 52 Week High
- ENLT $20.19
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- ENLT 62.94
- KYMR 48.27
- Support Level
- ENLT $16.87
- KYMR $28.06
- Resistance Level
- ENLT $20.19
- KYMR $30.28
- Average True Range (ATR)
- ENLT 0.63
- KYMR 1.65
- MACD
- ENLT 0.05
- KYMR -0.19
- Stochastic Oscillator
- ENLT 79.26
- KYMR 27.96
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.